The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
struggling to contain my laughter at this filing today
"We may offer, issue and sell from time to time up to $250,000,000, or its equivalent in any other currency, currency units, or composite currency or currencies, of our common shares, "
Interesting to see that the FDA have given ProventionBio another chance. Stock rose 30% on news.
TLSA are also following the diabetes route now.
https://www.nasdaq.com/articles/why-provention-bio-stock-skyrocketed-today?amp
I notice on ADVFN some of the BOD are getting flack for previously sucking the cash out.
A quick search of Willy jules Simon reveals he is named in the paradise papers.
Not that I really care about that but after another search I note he is also a director of stem printer sciences Ltd which doesn’t show on companies house unless I am mistaken (shows on endole)
He is the sole director of stemprinter sciences. What is going on?
I’m no expert but all sounds like to me that the brokers have bought and sold shares they did not have, just saying like! Not a Tils problem.
Come on you Tils .
Hi Bradders
I am in AJ Bell and my Accustem are showing zero value but at the consolidated value of 20:1 so phone AJ Bell Dealing Services they should be able to help you
Good Luck
StarKnight
Bradders64
Mine still show in my account as 30,000 accustem, which matches my TILS holding in Oct/Nov 20. They have not yet been consolidated or given any value. This will occur when they list on the Nasdaq?????
I cant see how you've ended up with 89. As I see it the 4000 shares for you, which will become 200 after consolidation.
BB
I've been struggling to work this out myself. Just a chunk of cash wiped off my account with nothing obvious in return beyond some small change value of TLSA!
sorry purchase dates were 2020 not 2021
Hi i wonder if someone could kindly help me understand this split and consolidation ?
Its not big numbers but i just dont understand how its all been done ?
So i held 4000 old shares which i bought in two 3421 5/2/21 and 579 on 27/08/21. I thought all these qualified for 1 free accustem share so 2000. However i have just 89 shares allocated in my dealing account ....no matter how i try to calculate it i just cant see how it gets to 89 ? can someone please help me understand it ? at least if i know a bit more i can ring AJB and sort it . Thanks in advance .
Would it not be in GC s interest to let the share price tumble further and then start the buyback at say 60cent. Im concerned how the company control newsflow and buyback to theor advantage.
Let's hope it does recover pretty soon so we dont have to listen to your daily moaning.
I'd get onto your broker as this delay is down to them. My 2 UK brokers are fully tradable.
Really don't get why you keep on mentioning me. You must be very bitter that an investment that you made didn't go as you wanted it to. Take the blame that you dont understand how long drug development takes and nobody made you buy this apart from yourself.
Your point about the fireside chat is again naive. Why would a US scientist talk about a UK broker issue on call to get institutions to invest.?
Have a listen to this link, but I'm sure you won't as it will take so much longer than your constant, repetitive moaning. Educate yourself before investing in the future.
https://microcapclub.com/2021/02/getting-started-in-life-science-investing-with-dr-david-sable/
Bo, the BioPharma sector has been down across the board. Logic says that will turn at some point.
We are all in charge of our own investment decisions ultimately.
No point trying to bait a guy who does some good research behind the scenes on behalf of investors.
He or others can’t control news flow from the company and on that point, I do agree with you. Some of the comms and the handling of the Accustem demerger haven’t been great.
Just under a year ago, (early Feb) the SP was sitting pretty and most people had a chance to exit then with a decent profit.
Only ourselves to blame, I still kick myself for not selling TILS when it went to nearly £3.
Loyalty aside, that should have been an obvious sell which I missed.
If you look across most chat boards at the moment, there are loads of people who have been wounded by the downturn in the markets.
Some are trapped in stocks which are unlikely to turn.
At least we are cashed up here and there are positive signs ahead in the pipeline.
We also have Accustem for a lot of us! Or maybe I shouldn’t have mentioned the A word haha!
Since the Nasdaq IPO, and UK shares still not able to trade with HL.
453 days since Accustem demerger.
Where’s that plumber gone & all the other serial rampers now?
Nothing mentioned about Accustem or UK shares again at the fireside shaft?
Scumbags. Total scumbags. If this recovers at all I am out and gone.
Worst performing share I have seen in the last 12 months. The whole sector is down but the mis-management here is just farcical.
Daveycaferacer you have been in this one since Accustem was spun off haven't you? I remember your name from way back.
In which case you will know and remember that the shares were given on a one for one basis free to TILS shareholders. There may have been a consequential drop in TILS SP at the time but it was not "taken from shareholders without compensation". And if course there was plenty of notice of it happening so shareholders could have got out if it didn't suit.
I had TILS but sold them shortly after getting the 19k free shares. I wish they'd get on with monetising it but I'm not expecting them to be worth much.
My take on this Dan, is that I’ve been here from the beginning and it seems like we are back to the beginning again but a lot further along the road with the products and still fully cashed up.
I will be excited to hear the results of the precision bio hook up , the results of MS trial, could be huge!!, Milciclib is still in the running with another trial ,which is what I invested in to start, So I am really happy with progress.
The buy back of $5 mill of shares on the open market is , to me, a master stoke! Genius.
These guys are not a scam they still have major products targeted in a $150 + Billion markets.
Alls well for me.
I've lost track of the shenanigans this company has played in the past two years. They need to focus on clinical development and either the disposal of Accustem or getting it to market instead of all the ludicrous corporate game playing they have engaged in
I've received nothing re. Accustem nor has it been mentioned anywhere
My main concern is how the transfer has been calculated? Why such a large portion has been liquidated to a value of £0.00 and then 1 share of TLSA per every 2 shares of TILS?
hi Niqash - you should have received your zero value Accustem shares, an asset that appears to have been taken from Tiziana shareholders without compensation. I don't know how the court could agree to a capital reduction without any form of commitment by the company on the timescales for a listing so people's assets have a value other than zero.
First time coming back to this share in a while after losing hope - can anyone give a general overview of where we're at, what the mood is from us shareholder's and what the outlook is? The numbers aren't surprising but don't make for pretty reading from where we were 18 months ago.
Any replies appreciated
Fireside chat, lots of info, even I can understand the science better after all these years, not surprised they are excited.
Could not understand Yuan but hay ho Kunwar came up trumps.
If the SP stays low , no matter, Tlsa will buy $5mill cheap shares and sell them to finance next year
PMSL. Genius!!
Im glad you mentioned the long awaited allocation of shares in Accustem. I have tried contacting the company's Finance Director (Keeran Shah) by phone and email to info@tizianalifesciences.com without receiving the courtesy of a reply regarding the listing and allocation of Accustem Shares to no avail. Is something dodgy going on and do we have any recourse?
can anyone explain why such a large portion of my shares have been liquidated for £0.00... Just seems like I've been screwed over..
Also now this is complete will we ever receive the Accustem shares we're owed?
Maybe some of that came from the licence agreement with Precision? Did like that he stated that they don't need any cash!
It was actually very good. Reminds me of 2020 and all the potential we saw.
Just a few points:
1. MS trial on 1st patient not only safe but patient showed clinical improvement. Data for 6 months of usage from this trial will be release in Q2 and they plan to do more trials in Europe.
2. IND for Crohns is being submitted - guess that might be the next RNS
3. Currently have $40m in the bank and costs this year for all the trials will be $28m - so fully funded going forward.
2021 was a train smash but it certainly looks like the good Dr has got his mojo back for 2022!
Approx $40m in cash. Where did that come from?
Q1 & Q2 has a bit of news to offer that may be significant on the MS data front.
Will it be on time? Who knows, but I’ll hang around.
GLA
BB